TERRE-DES-FEMMES
9.5.2019 09:02:11 CEST | Business Wire | Press release
TERRE DES FEMMES, a world-wide women’s rights organization, launches the campaign „Rated by women“ for the elections of the European Parliament end of May. The EU-flag with its twelve stars becomes a rating tool showing the progress Europe has made and the distance it still has to go for the fulfillment of women’s rights. TERRE DES FEMMES criticizes conservative populist and nationalist movements, the general absence of a women’s rights agenda for the elections but calls on all Europeans to vote.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190509005097/en/
More than half of the population of the European Union are women and still women’s rights play no role in the current campaigns for the EU elections in 28 member states. TERRE DES FEMMES’ new campaign brings women’s rights back on the agenda. It calls on all candidates and parties to take a stand for more equality and engage in the fight against prostitution and violence.
For example, TERRE DES FEMMES gives Europe 8 out of 12 stars on the topic of parity/ gender equality, as with 36.1 per cent in the current European Parliament women are still underrepresented. Concerning prostitution only three EU-states have adopted a Sex Buyer Law that makes buying people for sex a criminal offence. So only one tenth of the stars on the flag shines. In case of violence against women, the rating system is put upside-down. As still one third of all women in Europe are affected by sexual and domestic violence, TERRE DES FEMMES gives Europe 4,5 stars. Four stars symbolize the women affected, another half a star the high number of unreported cases.
The campaign was launched in Berlin in front of the German Parliament and is travelling Europe with stops in Amsterdam, Brussels, Paris, Strasbourg, Prague, Vienna, Bratislava, Budapest, and Munich.
“Europe has made an immense progress in women’s rights but there is still need for action. Our campaign wants to sensitize the voters for central themes like prostitution, parity and the prevention of violence against women. They belong to the agenda of all candidates for the EU elections. Especially in times with conservative populist and nationalist movements gaining grounds, it is important to vote and to continue the progress we have made”, says Christa Stolle, Managing Director, TERRE DES FEMMES.
Further information: http://www.ratedbywomen.eu/en.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20190509005097/en/
Contact:
Jerome Cholet McCann Worldgroup Germany jerome.cholet@mccann.de
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
